Drug name - Cabenuva Kit
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080551 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(6 months from now) | |
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(2 years from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(3 years from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 years from now) | |
| CN101346376A | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Jul, 2011
(11 years ago) | |
| CN101056673A | VIIV HLTHCARE | 4-[[4-[[4-(2-Cyanovinyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidyl]Amino] Benzonitrile Hydrochloride |
Jun, 2015
(7 years ago) | |
| CN1541215A | VIIV HLTHCARE | Hiv Inhibiting Pyrimidine Derivatives |
Aug, 2022
(a month ago) | |
| CN101816658A | VIIV HLTHCARE | Pyramine Derivatives For Inhibiting Hiv |
Aug, 2022
(a month ago) | |
| CN100509801C | VIIV HLTHCARE | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| CN101816658B | VIIV HLTHCARE | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| CN101068597A | VIIV HLTHCARE | Fumaric Acid Salt Of 4-((4-((4-(2-Cyanovinyl)-2, 6-) Dimethylphenyl Amido)-2- Pyrimidyl) Amido) Benzonitrile |
Sep, 2024
(1 year, 11 months from now) | |
| CN101060844A | VIIV HLTHCARE | Composition Of Rt Inhibitor And Nnrti Containing Pyrimidine |
Sep, 2024
(1 year, 11 months from now) | |
| CN101068597B | VIIV HLTHCARE | 4 - ((4 - ((4 - (2) -2, 6 -) Dimethylphenyl Amido) -2 - Pyrimidyl) Amido) Benzonitrile |
Sep, 2024
(1 year, 11 months from now) | |
| CN101060844B | VIIV HLTHCARE | Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors |
Sep, 2024
(1 year, 11 months from now) | |
| CN101212903B | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| CN101212903A | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| IN200400265P1 | VIIV HLTHCARE | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| IN222987B | VIIV HLTHCARE | A Pyrimidine Compound Of Formula (I) |
Aug, 2022
(a month ago) | |
| EP1663240B1 | VIIV HLTHCARE | Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors |
Jul, 2020
(2 years ago) | |
| EP1663240A1 | VIIV HLTHCARE | Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors |
Jul, 2020
(2 years ago) | |
| EP1632232B1 | VIIV HLTHCARE | Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile |
Feb, 2022
(7 months ago) | |
| EP1632232A1 | VIIV HLTHCARE | Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile |
Feb, 2022
(7 months ago) | |
| EP2298761A1 | VIIV HLTHCARE | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| EP2298761B1 | VIIV HLTHCARE | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| EP3808743B1 | VIIV HLTHCARE | Hiv Replication Inhibiting Pyrimidines |
Aug, 2022
(a month ago) | |
| EP3808743A1 | VIIV HLTHCARE | Hiv Replication Inhibiting Pyrimidines |
Aug, 2022
(a month ago) | |
| EP1789139A1 | VIIV HLTHCARE | Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile |
Sep, 2025
(2 years from now) | |
| EP1789139B1 | VIIV HLTHCARE | Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile |
Sep, 2025
(2 years from now) | |
| EP1852434B1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
| EP1852434A1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
| EP1852434A4 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
| EP3045206A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3187225A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3372281A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2527007A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2527007B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3284520B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3284520A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3372281B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3045206B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3187225B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117B8 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2465580A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2465580B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1950212A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(4 years from now) | |
| EP1950212A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(4 years from now) | |
| EP1950212B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(4 years from now) | |
| EP1419152A1 | VIIV HLTHCARE | Hiv Inhibiting Pyrimidines Derivatives |
Nov, 2026
(4 years from now) | |
| EP1419152B1 | VIIV HLTHCARE | Hiv Inhibiting Pyrimidines Derivatives |
Nov, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(8 years from now) | |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
Treatment: Treatment of hiv infection in adults
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.